Clinical pharmacology of monoclonal antibodies targeting anti-PD-1 axis in urothelial cancers.

Antibodies, Monoclonal / therapeutic use B7-H1 Antigen Carcinoma, Transitional Cell Humans Immunotherapy Programmed Cell Death 1 Receptor Urinary Bladder Neoplasms
PD-L1 inhibitors Pharmacodynamics Pharmacokinetics Urothelial cancer

Journal

Critical reviews in oncology/hematology
ISSN: 1879-0461
Titre abrégé: Crit Rev Oncol Hematol
Pays: Netherlands
ID NLM: 8916049

Informations de publication

Date de publication:
Dec 2019
Historique:
received: 22 04 2019
revised: 02 08 2019
accepted: 17 09 2019
pubmed: 8 11 2019
medline: 8 2 2020
entrez: 8 11 2019
Statut: ppublish

Résumé

Chemotherapy is the reference treatment for patients with advanced urothelial carcinoma, both in the neo-adjuvant and adjuvant settings; however, the overall outcome remains poor in this patient population. In the last few years, the addition of immune checkpoint inhibitors into the therapeutic armamentarium has changed the therapeutic landscape of several tumor types, including urothelial carcinoma. Many different molecules have been introduced on the market and several questions about immunotherapies are currently open and deserve a critical analysis. The current review article is aimed at describing the clinical pharmacology of monoclonal antibodies targeting PD-1 axis in urothelial malignancies to underline possible pharmacodynamic and pharmacokinetic differences among them.

Identifiants

DOI: 10.1016/j.critrevonc.2019.09.004 PMID: 31698313
pubmed: 31698313
pii: S1040-8428(19)30185-4
doi: 10.1016/j.critrevonc.2019.09.004
pii:
doi:

Substances chimiques

Antibodies, Monoclonal 0
B7-H1 Antigen 0
Programmed Cell Death 1 Receptor 0

Types de publication

Journal Article Review

Langues

eng

Sous-ensembles de citation

IM

Pagination

102812

Commentaires et corrections

Type : ErratumIn

Informations de copyright

Copyright © 2019 Elsevier B.V. All rights reserved.

Auteurs

Eleonora Rofi (E)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: eleonora0106@inwind.it.

Marzia Del Re (M)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: marzia.delre@gmail.com.

Elena Arrigoni (E)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: elena.arrigoni@hotmail.com.

Mimma Rizzo (M)

Department of Urology, University of Trieste, Cattinara Hospital, Trieste, Italy. Electronic address: rizzo.mimma@gmail.com.

Lorenzo Fontanelli (L)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: eimi.lore@me.com.

Stefania Crucitta (S)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: stefania.crucitta@gmail.com.

Giulia Gianfilippo (G)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: g.gianfilippo10@gmail.com.

Giuliana Restante (G)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: giuliana.restante@gmail.com.

Stefano Fogli (S)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: stefano.fogli@unipi.it.

Camillo Porta (C)

Department of Internal Medicine, University of Pavia, Italy; Division of Translational Oncology, I.R.C.C.S. Istituti Clinici Scientifici Maugeri, Pavia, Italy. Electronic address: camillo.porta@gmail.com.

Romano Danesi (R)

Unit of Clinical Pharmacology and Pharmacogenetics, Department of Clinical and Experimental Medicine, University of Pisa, Italy. Electronic address: romano.danesi@unipi.it.

Manuela Schmidinger (M)

Unit of Medical Oncology, Department of Internal Medicine, University of Wien, Austria. Electronic address: manuela.schmidinger@meduniwien.ac.at.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female

Evaluation of Low-Value Services Across Major Medicare Advantage Insurers and Traditional Medicare.

Ciara Duggan, Adam L Beckman, Ishani Ganguli et al.
1.00
Humans United States Aged Cross-Sectional Studies Medicare Part C

Effectiveness of Virtual Yoga for Chronic Low Back Pain: A Randomized Clinical Trial.

Hallie Tankha, Devyn Gaskins, Amanda Shallcross et al.
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH

questionsmedicales.fr › Acides aminés, peptides et protéines › Protéines › Globulines › Sérum-globulines › Immunoglobulines › Anticorps › Anticorps monoclonaux › Clinical pharmacology of monoclonal antibodies...
questionsmedicales.fr › Facteurs biologiques › Protéines et peptides de signalisation intercellulaire › Antigènes B7 › Antigène CD274 › Clinical pharmacology of monoclonal antibodies...
questionsmedicales.fr › Tumeurs › Tumeurs par type histologique › Tumeurs épithéliales épidermoïdes et glandulaires › Carcinomes › Carcinome transitionnel › Clinical pharmacology of monoclonal antibodies...
questionsmedicales.fr › Eucaryotes › Animaux › Chordés › Vertébrés › Mammifères › Eutheria › Primates › Haplorhini › Catarrhini › Hominidae › Humains › Clinical pharmacology of monoclonal antibodies...
questionsmedicales.fr › Thérapeutique › Biothérapie › Immunothérapie › Clinical pharmacology of monoclonal antibodies...
questionsmedicales.fr › Facteurs biologiques › Marqueurs biologiques › Antigènes de différenciation › Antigènes de différenciation des lymphocytes T › Récepteur-1 de mort cellulaire programmée › Clinical pharmacology of monoclonal antibodies...
questionsmedicales.fr › Maladies urogénitales › Maladies urologiques › Tumeurs urologiques › Tumeurs de la vessie urinaire › Clinical pharmacology of monoclonal antibodies...